Semnur Pharmaceuticals

SP-102 is a non-opioid injectable corticosteroid gel formulation designed to treat lumbar radicular pain, commonly known as sciatica. Unlike oral steroids, which can cause systemic side effects, SP-102 delivers medication locally to the affected nerve root with a single epidural injection. Semnur chose to build the entire company around this single asset because the clinical need for a safe, non-addictive sciatica treatment was substantial, with no new FDA-approved injectable therapies in the space for decades. The asset was licensed from Scilex Pharmaceuticals, and Semnur completed a Phase 3 pivotal trial called the C.L.E.A.R. study to support a potential New Drug Application.

Semnur Pharmaceuticals was acquired via a reverse merger with Vickers Vantage Corp. I in September 2022 to form Scilex Holding Company, which trades on Nasdaq. Semnur became a wholly-owned subsidiary, and its SP-102 asset was integrated into Scilex's commercial portfolio alongside products like ZTlido, a non-opioid lidocaine patch. The merger was structured as an equity roll-over, allowing Semnur's existing shareholders to convert their stakes into publicly traded Scilex stock (per the firm, September 2022). Scilex now controls all further development and commercialization of SP-102.

Investment and strategic decisions were led by founder and CEO Mahendra Shah, a pharmaceutical executive with experience in specialty pharmaceutical development. Because Semnur operated as a single-asset biotechnology company rather than a fund, the key decision-making centered on capital allocation for the SP-102 clinical program and the structuring of an eventual exit. The reverse merger with Vickers Vantage represented the firm's sole liquidity event. Day-to-day operational management remained with Shah and the clinical development team throughout the pivotal trial process.

Semnur did not allocate capital to external venture funds or biotech incubators. All capital was deployed directly into the clinical development, regulatory preparation, and pre-commercial planning for a single asset, SP-102. The firm's financial structure was that of a special-purpose public company rather than a diversified investment vehicle, meaning it never operated as a family office or a fund-of-funds. Investors participated through equity ownership in the public or pre-merger entity, not through limited partnership commitments.

Semnur did not pursue co-investment structures typical of family offices or private equity firms. Its primary partnership was a licensing relationship with its original parent, Scilex Pharmaceuticals, which granted it rights to SP-102. The firm also engaged contract research organizations and clinical trial site networks typical for late-stage pharmaceutical development. The reverse merger with Vickers Vantage Corp. I in 2022 served as the mechanism to bring in additional public-market capital and fully align Semnur with a commercial-stage biotech, rather than relying on syndicated equity rounds or venture co-investors.

Semnur's leadership chose to merge with Vickers Vantage Corp. I rather than sell to a pharmaceutical acquirer, likely because the transaction provided a clearer path to public-market valuation and retained equity upside for existing holders. By forming Scilex Holding Company, the combined entity could also cross-sell SP-102 alongside an existing commercial product in ZTlido, creating operational efficiencies that a pure acquisition might not have achieved. The SPAC structure gave Semnur a guaranteed closing timeline and access to a committed pool of capital during a period of high market volatility for clinical-stage biotech (per Endpoints News, 2022).

Semnur Pharmaceuticals exclusively targeted lumbar radicular pain, or sciatica, a specific condition within the broader pain management sector. The firm explicitly avoided opioid-based formulations, distinguishing itself in a category plagued by addiction concerns. It also did not develop therapies for oncology, autoimmune disorders, or neurological diseases outside the spine. The narrow focus was by design — to own one differentiated molecule through Phase 3 trials without diluting resources across a pipeline. Post-merger, Scilex Holding continues to focus on non-opioid pain treatments, suggesting the strategic avoidance of opioid assets is permanent.